Searched for
TRADING APIS
ETMarkets Smart Talk| From floor trading to AI algos: Why India’s retail traders are entering the automation era, says Shruti JainAI-powered algorithmic trading is becoming increasingly accessible to Indian retail investors, driven by Sebi’s regulatory framework, tradi...- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- India-China trade: The numbers behind the relationship as Xi visits DelhiChinese President Xi Jinping's visit highlights India-China trade's stark imbalance. India's imports from China vastly exceed its exports, ...
- Alpaca eyes 10x growth in India assets as GIFT City partners near launchYokokawa said Alpaca’s global AUC has been more than doubling year on year, while India AUC could expand “at least 10x” over the coming yea...
- “Whether we leave anyone behind”: Sameer Nigam’s blueprint for PhonePe’s second decadeAt Global Fintech Fest 2026, PhonePe founder‑CEO Sameer Nigam framed the company’s first ten years as the construction of India’s financial...
- Centralised interoperable digital layer can help bridge Rs 60 lakh crore MSME credit gap: ReportIndia's MSME sector faces a significant formal credit gap, with existing channels meeting limited debt demand. A new digital layer can conn...
- Retail algo trading gets a makeover: how APIs, AI and regulation are opening the door for Indian tradersRetail algo trading in India is becoming more accessible as broker APIs, cloud infrastructure, AI-assisted coding and low-cost platforms lo...
- ETMarkets Smart Talk| With 87.7% of F&O traders losing money, why systematic trading is becoming more relevant for retail investors, says Prashant ShahRetail traders face significant losses in India's derivatives market. Automation and AI tools offer solutions for consistent execution and ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos may rally over 21%, according to analystsWith the US market shedding weight overnight, the probability is high that Thursday will see another day of choppy trading. The best way to...
- No obvious sector to buy? So try an unconventional way: 7 stocks from different sectors with upside potential of up to 26%So, what to do if you cannot pick a sector to buy into? Forget about themes and waves, and go looking directly for individual businesses th...
- Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 croreFosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak...
- Gland Pharma shares: Promoter Fosun Pharma likely to divest 5% equity worth Rs 2,279 crore via block dealFosun Pharma plans to divest 5% equity in Gland Pharma through a Rs 2,279.5 crore block deal at Rs 2,763 per share. Gland Pharma reported a...
- Geopolitical shocks are forcing companies to rethink procurement intelligence: Claight CEOGeopolitical tensions, tariff uncertainty and repeated supply-chain disruptions are pushing global companies to move from periodic procurem...
- Sun Pharma to extend MFN pricing to US state Medicaid programmesSun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Rec...
- Coinbase's India return: How a bespoke rupee on-ramp changes the game for foreign exchangesOperating under a fresh local entity fully registered with India's Financial Intelligence Unit (FIU-IND) and compliant with local tax frame...
- Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticost...
- Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with RazentaThe Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptiv...
- Pharmeasy-parent’s loss narrows in Q1, revenue up 10%API Holdings, parent of PharmEasy and Thyrocare, narrowed its Q1 FY27 loss to Rs 29.6 crore from Rs 145.4 crore a year earlier, while reven...
- India Inc should utilise FTAs, focus on value addition, diversify export markets, says govt officialIndustry must utilize free trade agreements for expanded market access and investment. Value addition and supply chain resilience are cruci...
- Pharmeasy parent clears Rs 1,050 crore debt, frees Thyrocare stake from pledgeThe debt repayment marks the latest step in API Holdings’ efforts to clean up its balance sheet after a difficult period struggling to rais...
Load More
